Nicox S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COX.PA research report →
About the company
Nicox S. A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health.
- CEO
- Michele Garufi
- IPO
- 1999
- Employees
- 32
- HQ
- Valbonne, FR
Price Chart
- Market Cap
- $29.04M
- P/E
- -13.72
- P/S
- 1.80
- P/B
- 5.50
- EV/EBITDA
- 1.40
- Div Yield
- 0.00%
- Gross Margin
- 38.99%
- Op Margin
- -81.33%
- Net Margin
- -14.39%
- ROE
- -51.16%
- ROIC
- -163.75%
- Revenue
- $5.24M · -38.93%
- Net Income
- $-27,759,000 · 36.57%
- EPS
- $-0.74 · 36.75%
- Op Income
- $-21,696,000
- FCF YoY
- -25.30%
- 52W High
- $2.09
- 52W Low
- $0.55
- 50D MA
- $0.66
- 200D MA
- $1.31
- Beta
- 0.97
- Avg Volume
- 196.98K
Get TickerSpark's AI analysis on COX.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our COX.PA coverage
Recent articles, reports, and earnings notes.
No research on COX.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate COX.PA report →Similar companies
Peers in the same neighborhood.